Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03947346 · ClinicalTrials.gov registry record
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 28
- Enrollment target
NCT03947346: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03947346 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03947346 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
Primary Outcome
urine collected from the first morning void will be used to assess urine creatinine
Interventions
- OTHER Urine sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2025-07-15 |
What the finished NCT03947346 record still lists
NCT03947346 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Urine sample is the first listed.
NCT03947346 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03947346 about?
NCT03947346 is a clinical study titled "Biomarkers of Renal Dysfunction in Neuroblastoma Survivors". The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or diseas...
What is the current status of trial NCT03947346?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-05-09. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT03947346?
The interventions under investigation include: Urine sample (OTHER).
Who is sponsoring clinical trial NCT03947346?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI